Jeffrey Weiss, MD
Allergy · Riverdale, NJNPI 1366625162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $472,579 of the $532,427 with a category attached, or 88.8%. 47 manufacturers reported payments, led by AstraZeneca at 54.6% of the total. Among allergy clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,342 payments — averaging $396.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$291K
- GSK$160K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Amgen$23K
- ADMA Biomanufacturing LLC$14K
- Novartis$13K
- plus $9K from 41 others
Across 53 payments — averaging $5711.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$147K
- AstraZeneca$89K
- Pfizer$24K
- Astrazeneca UK Limited$24K
- Novartis$18K
- Amgen$787
Across 2 payments — averaging $627.69 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$1K
What the payments were for
- Consulting fees$9,0072%
- Speaking & faculty fees$472,57989%
- Travel & lodging$22,7944%
- Food & beverage$27,6735%
- Education$3750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$532,427 in reported general payments places this provider in the 95th percentile of 35 allergy providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 26 | $60,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $37,659 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $16,995 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $13,630 |
| Arnuity ElliptaFluticasone Furoate | 42 | $10,382 |
| Epinephrine | 55 | $8,940 |
| Cromolyn Sodium | 12 | $4,956 |
| DuleraMometasone/Formoterol | 12 | $4,812 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 27 | $3,648 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,629 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,359 |
| Montelukast Sodium | 348 | $3,329 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,933 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,257 |
| Mometasone Furoate | 14 | $1,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $159,692 | $65,036146 claims |
| Hikma Pharmaceuticals USAEpinephrine | $31 | $8,94055 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $45 | $4,95612 claims |
| MerckDulera | $30 | $4,81212 claims |
| AstraZenecaSymbicort | $290,961 | $3,62911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 allergy providers in New Jersey.
Other allergy in Riverdale
- John OppenheimerCedar Knolls$922K
- Jay KashkinFair Lawn$436K
- Gregory TociMarlton$317K
- Eugene GattiMarlton$43K
- Howard DruceSomerville$37K
- Shashank ShethVoorhees$33K
- Donatella GraffinoCedar Knolls$15K
- Maria Lania-HowarthVoorhees$12K
- Jamie ZachariasSewell$11K
- Jun YangTinton Falls$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.